DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for gliosarcoma — screening already-approved drugs against its 27-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGliosarcoma maps to a 27-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gliosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NRAS proto-oncogene, GTPase (NRAS) — NRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZIO · 1.55 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
Gliosarcoma is a rare and aggressive brain tumour, representing approximately 2% of cases classified as glioblastoma. It is characterised by a biphasic histologic pattern consisting of a gliomatous and a sarcomatous component. In most instances the sarcomatous component is fibrosarcoma, though osteosarcomatous differentiation has been rarely reported. Recent molecular studies suggest that both components may derive from a single precursor cell clone that progresses into two subclones with distinct morphologic features during tumour evolution, though the events determining this splitting remain to be investigated.
Treatment of gliosarcoma follows the paradigm for glioblastoma, with recommendations for maximal allowable resection followed by post-operative radiation therapy to the operative bed with concurrent temozolomide. No survival or response rate data are provided in these abstracts. The prognosis is described as poor, and the tumour presents unique challenges due to its complex histological features and aggressive behaviour.
One case report describes transdural and metastatic intracranial meningeal spread following resection of a temporal frontal lobe gliosarcoma. No other clinical trial data, patient outcomes, or drug-specific results are reported in these abstracts. The abstracts contain no concrete numbers for survival, response rates, or sample sizes.
What is still missing are prospective clinical trials with survival data, any evidence that current or repurposed drugs improve outcomes beyond standard chemoradiation, and a clear molecular stratification that might identify which patients, if any, respond to specific therapies. The events that cause the original tumour clone to split into two histologic populations also remain unknown.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2006 · 26 citations
Gliosarcoma with features of osteoblastic osteosarcoma: a review.
AbstractCONTEXT: Gliosarcoma is a rare tumor of the central nervous system characterized by a biphasic histologic pattern, consisting of a gliomatous and a sarcomatous component, respectively. In most instances the sarcomatous component is represented by a fibrosarcoma, but other stromal malignancies have also been described. Osteosarcomatous differentiation in gliosarcoma has been rarely reported. OBJECTIVE: To review characteristic radiologic and histopathologic features of this rare neoplasm, to debate about possible differential diagnoses that should be taken into consideration, and to provide an overview of the potential histopathogenesis of gliosarcomas. DATA SOURCES: Relevant articles indexed in PubMed (National Library of Medicine) and reference medical texts. CONCLUSIONS: Recent molecular studies suggest that sarcomatous and gliomatous components of gliosarcoma might be derived from a single precursor cell clone, progressing in 2 subclones with distinct morphologic features during tumor evolution. Nonetheless, events determining splitting of the original clone into 2 histologic populations remain to be investigated.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
Gliosarcoma: Unraveling the Enigmatic Brain Tumor
AbstractGliosarcoma is a rare and aggressive brain tumor characterized by the coexistence of glioblastoma and sarcoma-like elements within the central nervous system. This malignant neoplasm presents unique challenges in diagnosis and treatment due to its complex histological features and aggressive behavior. This article provides an overview of gliosarcoma, including its histological characteristics, clinical presentation, diagnostic methods, treatment options, and ongoing research efforts to improve patient outcomes. Despite its poor prognosis, advances in targeted therapies and multidisciplinary approaches offer hope for enhancing the management of this challenging disease.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
Gliosarcoma: Unraveling the Enigmatic Brain Tumor
AbstractGliosarcoma is a rare and aggressive brain tumor characterized by the coexistence of glioblastoma and sarcoma-like elements within the central nervous system. This malignant neoplasm presents unique challenges in diagnosis and treatment due to its complex histological features and aggressive behavior. This article provides an overview of gliosarcoma, including its histological characteristics, clinical presentation, diagnostic methods, treatment options, and ongoing research efforts to improve patient outcomes. Despite its poor prognosis, advances in targeted therapies and multidisciplinary approaches offer hope for enhancing the management of this challenging disease.
Neurosurgery Cases and Reviews · 2022 · 0 citations · open access
A Case of Transdural and Metastatic Intracranial Meningeal Spread following Resection of a Temporal Frontal Lobe Gliosarcoma
AbstractGliosarcoma is a very uncommon primary brain malignancy and is considered a subtype of glioblastoma. It represents approximately 2% of cases classified as glioblastoma. Treatment of gliosarcoma follows the paradigm for glioblastoma with recommendations for a maximal allowable resection followed by post-operative radiation therapy to the operative bed with concurrent temozolomide.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
